Precision X-Ray, Inc.

Precision X-Ray, Inc. is proud to have hosted another successful global training for service technicians. Our very own Sal Gentile and Jason Manning shared their extensive knowledge and expertise, ensuring that customers worldwide continue to receive Class A service. Thank you to everyone who traveled from across the pond to learn all about Precision X-Ray products: Michael Fischbacher from AXIM , Emanuel Marius BOGOI from TECNASA, Tecnologías Asociadas, Martin Coudert and Philippe Billie from Tromp Medical France and Lucie Hanyasova from accela.eu Your dedication and enthusiasm help us support a better future in scientific innovation and research! #PrecisionXray, #CustomerService

Precision X-Ray, Inc. is excited to be exhibiting at the 2024 AABB Annual Meeting in Houston!   Join us October 19-22 at the George R. Brown Convention Center to discover the latest innovations in the blood and biotherapies field.   Visit us at Booth 239, where we'll be showcasing the RADGIL2 X-Ray Blood Irradiator! As the exclusive US distributor, we’re proud to partner with Gilardoni X-ray and Ultrasounds to bring you this cutting-edge solution. Designed to prevent transfusion-related diseases like TA-GvHD, RADGIL2 is a safer, more efficient alternative to traditional Cesium-137 irradiators.   We can't wait to see you in Houston! 🌍 #AABB2024 #RADGIL2 #BloodTherapies #MedicalResearch #PrecisionXRay

Exciting News: Precision X-Ray, Inc. Partners with Gilardoni X-ray and Ultrasounds to Bring X-Ray Blood Irradiation to the US! We are excited to announce that Precision X-Ray, Inc. has been awarded exclusive distribution rights for the RADGIL2 X-Ray Blood Irradiator in the United States. Brought to the US in partnership with Gilardoni X-ray and Ultrasounds, RADGIL2 is designed specifically to prevent transfusion-related diseases like Transfusion-associated Graft vs. Host Disease (TA-GvHD), while providing a safer, more efficient alternative to traditional Cesium-137 based irradiators. Key features of RADGIL2 include: ✅ High dose rate for faster, more efficient blood irradiation. ✅ Rotating canister technology for precise, uniform dose distribution. ✅ Integrated data management system maintains security and provides customized reports “We’re proud to partner with Gilardoni to expand our presence in the medical field and deliver safer, more effective solutions like the RADGIL2,” said Viktoriya Baytser, CEO of Precision. Read the full press release: https://lnkd.in/e8jPj8Fv For more information on RADGIL2 and Precision X-Ray, Inc.'s full range of X-Ray products and solutions, visit precisionxray.com. #BloodIrradiation #PrecisionXRay #Gilardoni

Supporting Breast Cancer Awareness Month: A Mission Close to Our Hearts October is Breast Cancer Awareness Month, and at Precision X-Ray, Inc., we are deeply committed to advancing the fight against cancer through cutting-edge technology and innovation. Our X-ray irradiators play a crucial role in cancer research, helping scientists develop better treatments and improve patient outcomes. As we raise awareness, it’s a reminder of the importance of early detection and continued research in this field. Together, we can make strides in beating this disease and supporting those affected by breast cancer. Let’s continue to spread awareness and support each other in this important cause. #BreastCancerAwareness #PrecisionXRay #CancerResearch #FightAgainstCancer

A collaborative study conducted at Universit�� de Caen Normandie, Centre François Baclesse, The Horia Hulubei National Institute of Physics and Nuclear Engineering - IFIN-HH, and the University of Bucharest utilized the Precision X-Ray, Inc. CellRad Irradiator to evaluate the differential effects of DNA damage repair inhibitors and high linear energy transfer (LET) irradiation on chondrosarcoma and chondrocyte cells.   Chondrosarcoma, a rare malignant tumor that develops in bone and cartilage, is primarily treated through surgical removal, often with a margin of healthy tissue. However, when complete surgical resection isn't feasible, radiation therapy and chemotherapy are combined with surgery, though their effectiveness is generally low. Therefore, new therapeutic strategies are essential in these cases. This research aims to explore the potential of Olaparib (PARP inhibitors) to radiosensitize chondrosarcoma and chondrocyte cells, particularly focusing on how different IDH statuses respond to C-ion and X-ray radiation.   For this study, the chondrosarcoma OUMS27 cell line, the JJ012 cell line (primary grade II chondrosarcoma), and the chondrocyte cell line MC615 were irradiated with X-rays at doses ranging from 1 to 6 Gy using our CellRad system (Precision X-ray, Madison, CT, USA). The system was equipped with a copper filter, operating at a tube tension of 129 keV and an intensity of 4.7 mA, corresponding to a dose rate of 1 Gy/min.   The study reveals the complexity of DNA repair mechanisms and cell responses to DNA damage, dependent on LET and the specific DNA repair inhibitors used. PARP inhibition showed promising results, especially in combination with X-ray irradiation. This study demonstrates the critical role the Precision X-ray CellRad system plays in understanding the mechanisms behind chondrosarcoma’s resistance to treatments.   We are proud to see how Universit�� de Caen Normandie and the University of Bucharest maximize the potential of our technology to discover new approaches in cancer treatment!   Link: https://lnkd.in/eKHtT3s2 #CancerResearch #Radiotherapy #PrecisionXRay #CellRad #NormandieUniversite #Chemotherapy

We are happy to announce yet another successful installation of the Precision X-Ray, Inc. SmART+, small animal IGRT system at the University of Calgary! Dr. Michael Monument, Director of the Integrated Sarcoma Research Program (iSARP), in collaboration with the Alberta Cancer Foundation, is on a mission to accelerate clinical sarcoma research initiatives and develop precision oncology and novel immunotherapy opportunities for high-risk sarcoma patients. With a particular interest in therapeutic approaches to activate the STimulator of INterferon Genes (STING) pathway within sarcomas as a clinically relevant single-agent therapy or in combination with radiation and other immune-based therapies, the SmART+ will be instrumental in their work to inflame the sarcoma microenvironment. We are so proud to be part of research that is aimed to change the course of cancer treatment. #RadiationTherapy #CancerResearch #PrecisionXRay #MedicalInnovation

We are happy to announce yet another successful installation of the Precision X-Ray, Inc. SmART+, small animal IGRT system at the University of Calgary! Dr. Michael Monument, Director of the Integrated Sarcoma Research Program (iSARP), in collaboration with the Alberta Cancer Foundation, is on a mission to accelerate clinical sarcoma research initiatives and develop precision oncology and novel immunotherapy opportunities for high-risk sarcoma patients. With a particular interest in therapeutic approaches to activate the STimulator of INterferon Genes (STING) pathway within sarcomas as a clinically relevant single-agent therapy or in combination with radiation and other immune-based therapies, the SmART+ will be instrumental in their work to inflame the sarcoma microenvironment. We are so proud to be part of research that is aimed to change the course of cancer treatment. #RadiationTherapy #CancerResearch #PrecisionXRay #MedicalInnovation

We are pleased to announce Precision X-Ray, Inc.'s continued contribution to cancer research through the SAPPHIRE project at the University Proton Therapy Dresden (UPTD). For the first time, our SmART+ IB system has been integrated into the experimental proton beamline at UPTD, facilitating precise, image-guided radiation therapy experiments utilizing both proton and photon modalities. The SAPPHIRE project, with its optimized low-dose CT imaging, dosimetric characterization of photon and proton beams, and the establishment of a comprehensive quality assurance procedure, serves as a vital link between preclinical investigations and potential clinical applications. This integration enables comparative animal studies for translational radiobiology research and advancements in cancer therapy. We are proud to be amongst those like Elke Beyreuther, Elisabeth Bodenstein, Sebastian Gantz, Joshua D. Schilz, Moritz Schneider, et al who are intimately involved in this significant endeavor aimed at improving patient outcomes. Link to publication: https://lnkd.in/eh5E7x9p #RadiationTherapy #ProtonTherapy #CancerResearch #PrecisionXRay #MedicalInnovation

A collaborative study conducted by King's College London and Guy's and St Thomas' NHS Foundation Trust utilized the Precision X-Ray, Inc. SmART+ Irradiator to enhance early imaging responses to radiotherapy and detect radioresistant tumors using [18F]FSPG (L-glutamate) in head and neck squamous cell carcinoma (HNSCC). The research employed our technology to deliver precise radiation doses, allowing researchers to investigate early tumor responses. In vitro, FaDU HNSCC cells were treated in 96-well plates with a 12 cm × 12 cm beam (225 kV, 20 mA, 0.3 mm Cu filtered) at a dose rate of 5.63 Gy/min, resulting in a total cumulative dose of 2–10 Gy. This induced apoptotic cell death and oxidative stress. The precision of the SmART+ irradiator ensured accurate and reproducible dosing, leading to reliable data. In vivo, CT-planned targeted treatment was administered to mice with FaDU xenografts using two parallel-opposed 10 mm circular beams (225 kV, 20 mA, 0.3 mm Cu filtered) at a dose rate of 5.63 Gy/min. A total of 24 Gy was delivered in eight fractions of 3 Gy over 10 days, with a 2-day break after 5 fractions. In both the cell cultures and tumor-bearing mice, radiotherapy-induced oxidative stress coincided with a decrease in PET imaging signals, highlighting significant potential for advancing treatment and improving outcomes. This study demonstrates how the Precision X-Ray, Inc. X-ray SmART+ system is essential for identifying early biomarkers of radiation response, thereby advancing personalized cancer treatments. Proud to see King's College London and our technology driving new frontiers in cancer care! Great job to the team of Khrishanthne Sambasivan, Rizwan Farooq, MRSC, Jenasee Mynerich, Muhammet Tanc, Teresa Guerrero Urbano, Tim Witney, et al. for a job well done! Link: https://lnkd.in/eqqV2nKg #CancerResearch #Radiotherapy #PrecisionXRay #SmARTIrradiator #KingsCollegeLondon

Our MultiRad 225 was utilized in a study at the DKFZ German Cancer Research Center and Heidelberg University, exploring ultrahigh dose-rate radiation (UHDR) and its effects on hydrogen peroxide (H₂O₂) production, a significant source of oxidative stress and DNA damage. The study aimed to resolve the controversy between multiple studies and Monte Carlo simulations regarding the radiobiological mechanisms related to (H₂O₂) yield, which underline the FLASH effect. The MultiRad 225 was expertly utilized to produce X-rays at precise dose rates of 0.1 and 10 Gy/s, essential for the experimental setup, which also incorporated Carbon ion- and electron -beams. To achieve the required conditions, researchers removed the filter to increase the dose rate and positioned samples closer to the source using an adjustable rack, optimizing the irradiator’s capabilities. The X-ray tube was meticulously set at 200 kV with a current of intensity of 17.8 mA, delivering an irradiation dose of around 30 Gy per sample. Joao Seco, with his team Tengda Zhang, Christina Stengl, Larissa Derksen, Kristaps Paļskis, Konstantinos Koritsidis, Sebastian Adeberg, Dr. Ulrike Theiß, Maria Francesca Spadea, Elpida Theodoridou, and others demonstrated that UHDR consistently reduces (H₂O₂) levels compared to conventional irradiation, validating the theory that the FLASH technique spares normal tissue due to lower reactive oxygen species (ROS) production. This reduction occurs because instantaneous radical concentrations differ from the long-lived radical theory suggested by Monte Carlo simulations. This setup was crucial in our understanding of radiation’s impact on reactive oxygen species. We are proud that our MultiRad 225 remains a trusted tool in cutting-edge radiation research, enabling groundbreaking scientific discoveries! Read the full publication here: https://lnkd.in/eWmUfzT6   #RadiationResearch #PrecisionXRay #MultiRad225 #Radiobiology